IKENA ONCOLOGY INC (IKNA) Stock Price & Overview
NASDAQ:IKNA • US45175G1085
Current stock price
The current stock price of IKNA is 1.43 USD. Today IKNA is up by 4.38%. In the past month the price increased by 6.72%. In the past year, price decreased by -15.88%.
IKNA Key Statistics
- Market Cap
- 15.987M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.28
- Dividend Yield
- N/A
IKNA Stock Performance
IKNA Stock Chart
IKNA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IKNA. When comparing the yearly performance of all stocks, IKNA turns out to be only a medium performer in the overall market: it outperformed 47.83% of all stocks.
IKNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IKNA. IKNA has a great financial health rating, but its profitability evaluates not so good.
IKNA Earnings
IKNA Forecast & Estimates
IKNA Groups
Sector & Classification
IKNA Financial Highlights
Over the last trailing twelve months IKNA reported a non-GAAP Earnings per Share(EPS) of -3.28. The EPS decreased by -121.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.79% | ||
| ROE | -39.1% | ||
| Debt/Equity | 0 |
IKNA Ownership
IKNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.12 | 846.194B | ||
| JNJ | JOHNSON & JOHNSON | 20.64 | 576.236B | ||
| MRK | MERCK & CO. INC. | 23.12 | 294.041B | ||
| PFE | PFIZER INC | 9.06 | 156.828B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.24 | 121.027B | ||
| ZTS | ZOETIS INC | 16.01 | 49.233B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.97 | 27.078B | ||
| VTRS | VIATRIS INC | 5.2 | 15.394B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.99 | 12.22B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.402B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.647B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.596B | ||
| CORT | CORCEPT THERAPEUTICS INC | 45.51 | 4.098B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IKNA
Company Profile
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Company Info
IPO: 2021-03-26
IKENA ONCOLOGY INC
50 Northern Ave.
Boston MASSACHUSETTS 02210 US
CEO: Mark Manfredi
Employees: 18
Phone: 18573438292
IKENA ONCOLOGY INC / IKNA FAQ
What does IKENA ONCOLOGY INC do?
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Can you provide the latest stock price for IKENA ONCOLOGY INC?
The current stock price of IKNA is 1.43 USD. The price increased by 4.38% in the last trading session.
What is the dividend status of IKENA ONCOLOGY INC?
IKNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IKNA stock?
IKNA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for IKENA ONCOLOGY INC?
IKENA ONCOLOGY INC (IKNA) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for IKNA stock?
IKENA ONCOLOGY INC (IKNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.28).